Seeking Alpha

EU regulators OK Novartis' (NVS -1%) Afinitor drug for treating women with a certain type of...

EU regulators OK Novartis' (NVS -1%) Afinitor drug for treating women with a certain type of breast cancer. The latest approval adds to backing from the FDA for breast cancer, and to authorization for four other types of the disease. Kepler Capital Markets analyst Martin Voegtli reckons Afinitor is on course to be a blockbuster by next year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|